Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

These stocks can be a rollercoaster, and StockStory is here to guide you through the ups and downs. Keeping that in mind, here is one volatile stock that could deliver huge gains and two that might not be worth the risk.

Two Stocks to Sell:

Bally's (BALY)

Rolling One-Year Beta: 1.13

Headquartered in Providence, Rhode Island, Bally's Corporation (NYSE: BALY) is a diversified global casino-entertainment company that owns and manages casinos, resorts, and online gaming platforms.

Why Do We Avoid BALY?

1. Muted 2% annual revenue growth over the last two years shows its demand lagged behind its consumer discretionary peers
2. Eroding returns on capital from an already low base indicate that management’s recent investments are destroying value
3. Short cash runway increases the probability of a capital raise that dilutes existing shareholders

Bally's is trading at $14.03 per share, or 10.9x forward EV-to-EBITDA. Check out our free in-depth research report to learn more about why BALY doesn’t pass our bar.

TD SYNNEX (SNX)

Rolling One-Year Beta: 1.17

Serving as the crucial middleman in the technology supply chain, TD SYNNEX (NYSE: SNX) is a global technology distributor that connects thousands of IT manufacturers with resellers, helping businesses access hardware, software, and technology solutions.

Why Does SNX Worry Us?

1. Large revenue base makes it harder to increase sales quickly, and its annual revenue growth of 4.2% over the last two years was below our standards for the business services sector
2. Performance over the past five years shows its incremental sales were less profitable as its earnings per share were flat
3. Lacking free cash flow generation means it has few chances to reinvest for growth, repurchase shares, or distribute capital

At $172.14 per share, TD SYNNEX trades at 11.7x forward P/E. If you’re considering SNX for your portfolio, see our FREE research report to learn more.

One Stock to Watch:

Astrana Health (ASTH)

Rolling One-Year Beta: 1.16

Formerly known as Apollo Medical Holdings until early 2024, Astrana Health (NASDAQ: ASTH) operates a technology-powered healthcare platform that enables physicians to deliver coordinated care while successfully participating in value-based payment models.

Why Could ASTH Be a Winner?

1. Impressive 47.7% annual revenue growth over the last two years indicates it’s winning market share this cycle
2. Notable projected revenue growth of 34% for the next 12 months hints at market share gains
3. Earnings growth has comfortably beaten the peer group average over the last five years as its EPS has compounded at 11.6% annually

Astrana Health’s stock price of $18.59 implies a valuation ratio of 6.5x forward EV-to-EBITDA. Is now the time to initiate a position? See for yourself in our in-depth research report, it’s free.

High-Quality Stocks for All Market Conditions

The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 9 Market-Beating Stocks. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.